Clinical Trial

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Trial Details
NCT Number NCT07154381
Lead Sponsor University Hospital, Essen
Conditions Cardiac Amyloidosis
Enrollment 25 participants
Start Date 2019-12-09
Primary Completion 2025-10 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-04